Bispecific antibody (BsAb) is a protein made in a lab that is made up of pieces of two different monoclonal antibodies and can bind to two different types of antigen. Immunotherapy for cancer is the use of bispecific antibody that has been studied the most. Most of the time, BsAb is used to treat lung, breast, and stomach cancer. A bispecific antibody binds to and kills both the killing cell and the target tumor cell at the same time. The development of bispecific antibodies as a highly advanced way to use the same molecule for two different targeting strategies. Bispecific antibodies can lead T lymphocytes to tumor cells, disrupt two signaling pathways, and deliver payloads. The U.S. FDA authorized two bispecific antibody treatments, catumaxomab and blinatumomab, which will boost their markets. Bispecific antibodies are fragment, symmetric, or asymmetric. Nanobody DART and BiTE fragment bispecific antibody studies are underway. Tetravalent BsAb-DVD and DAF symmetric antibodies are being studied. Bispecific antibodies are growing due to monoclonal antibodies' medication resistance and therapeutic failure. Thus, the bispecific antibody market is expected to grow rapidly.
Prominent Companies in the Bispecific Antibodies Industry:
1. Amgen, Inc.
Amgen, Inc. is an American multinational biopharmaceutical company founded in 1980 and is headquartered in California, United States. It operates in 100 countries and has global presence. In July 2021, Amgen and Teneobio announced that Amgen will buy Teneobio. Teneobio is a privately held biotechnology business in the clinical stage that is making a new type of biologics called Human Heavy-Chain Antibodies.
2. Bayer AG
Bayer AG is a German multinational pharmaceutical and biotechnology company founded in 1863 and it is one of the largest pharmaceutical companies in the world. The headquarter is in Leverkusen, Germany. Bayer is represented in 83 countries including Canada, Mexico, Germany and Switzerland.
3. Dow Pharmaceutical Solutions
Dow Pharmaceutical Solutions was founded in 1897 and headquartered in Michigan, U.S. It operates in about 160 countries.
4. ImmunGene, Inc.
ImmunGene, Inc. is a privately owned biotechnology business that works on developing antibody-cytokine fusion technology and monoclonal antibody-based therapies to treat cancer, autoimmune disorders, and other diseases. ImmunGene is working on multiple projects that are at different stages of development. It was founded in 2007 and headquartered in California, United States.
5. Immunocore Limited
Immunocore Limited It was founded in 2008 as a spinoff from MediGene AG, Avidex was bought in 2006. It is headquartered in England, U.K. It operates in over 30 countries. In Jan 2022, Immunocore Holdings plc, a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies for the treatment of a broad range of diseases, including cancer, autoimmune and infectious diseases, today announces FDA approval of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM)
6. Merck & Co., Inc.
Merck & Co., Inc. is an American multinational pharmaceutical company and is named for Merck Group, was founded in 1668, and headquartered in New Jersey, United States. It operates in 66 countries. In Dec 2022, Merck and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd) have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer.
7. Novartis AG
Novartis AG was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis had its headquarters at Basel, Switzerland. It improves and prolongs lives. Novartis AG has partners in about 140 countries. In September 2022, Novartis announced today that it will invest in next-generation biotherapeutics by establishing a fully integrated, USD 300 million scientific environment that will strengthen its capacity and capabilities for early technical development of biologics .
8. Pfizer, Inc.
Pfizer, Inc. is an American multinational pharmaceutical and biotechnology corporation, founded in 1849. The headquarter is in Williamsburgh, New York. It operates to over 181 countries. Pfizer Inc. announced new data in June 2022 from a planned interim analysis of the Phase 2 MagnetisMM-3 registration-enabling trial of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) whose disease is resistant to at least one agent in each of the three major classes of medications approved for the disease.
9. F. Hoffmann-La Roche AG.
F. Hoffmann-La Roche AG. which is commonly known as Roche is a Swiss multinational healthcare company, founded in 1896. The company headquarters are located in Basel, Switzerland. It actively operates in over 130 countries. FDA approves Roche's Columvi, the first and only bispecific antibody with a fixed-duration treatment for persons with relapsed or resistant diffuse large B-cell lymphoma, in June 2023.
*Definition: A bispecific monoclonal antibody (BsMAb, BsAb) is a synthetic protein that can simultaneously bind to two distinct antigen types or two distinct epitopes on the same antigen. Typically, naturally occurring antibodies only target a single antigen. BsAbs can be produced in a variety of structural formats.
